Optimizing the performance of ⁶⁸Ga labeled FSHR ligand in prostate cancer model by co-administration of aprotinin

References

• Agris PF, Guenther RH, Sierzputowska-Gracz H, Easter L, Smith W, Hardin CC, Santa-Coloma TA, Crabb JW, Reichert LE. Jr. 1992. Solution structure of a synthetic peptide corresponding to a receptor binding region of FSH (hFSH-beta 33-53). J Protein Chem. 11(5):495–507.
   PubMedGoogle Scholar
• Briquez PS, Lorentz KM, Larsson HM, Frey P, Hubbell JA. 2017. Human Kunitz-type protease inhibitor engineered for enhanced matrix retention extends longevity of fibrin biomaterials. Biomaterials. 135:1–9.
   PubMed Web of Science ®Google Scholar
• Casas-Godoy L, Sandoval G. 2016. Proteases and their inhibitors: from basic to high throughput screening. Comb Chem High Throughput Screen. 19(8):636–643.
   PubMed Web of Science ®Google Scholar
• Ghinea N. 2018. Vascular endothelial FSH receptor, a target of interest for cancer therapy. Endocrinology. 159(9):3268–3274.
   PubMed Web of Science ®Google Scholar
• Hedstrom L. 2002. Serine protease mechanism and specificity. Chem Rev. 102(12):4501–4524.
   PubMed Web of Science ®Google Scholar
• Hong S, Zhang X, Chen J, Zhou J, Zheng Y, Xu C. 2013. Targeted gene silencing using a follicle-stimulating hormone peptide-conjugated nanoparticle system improves its specificity and efficacy in ovarian clear cell carcinoma in vitro. J Ovarian Res. 6(1):80.
   PubMedGoogle Scholar
• Ingels A, Leguerney I, Cournède P-H, Irani J, Ferlicot S, Sébrié C, Benatsou B, Jourdain L, Pitre-Champagnat S, Patard J-J, et al. 2020. Ultrasound molecular imaging of renal cell carcinoma: VEGFR targeted therapy monitored with VEGFR1 and FSHR targeted microbubbles. Sci Rep. 10(1):7308.
   PubMed Web of Science ®Google Scholar
• Kanellopoulos P, Kaloudi A, Jong M, Krenning EP, Nock BA, Maina T. 2020. Key-protease inhibition regimens promote tumor targeting of neurotensin radioligands. Pharmaceutics. 12(6):528.
   Web of Science ®Google Scholar
• Kanellopoulos P, Nock BA, Krenning EP, Maina T. 2020. Optimizing the profile of [(99m)Tc]Tc-NT(7-13) tracers in pancreatic cancer models by means of protease inhibitors. IJMS. 21(21):7926.
   Google Scholar
• Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, Czernin J, Haberkorn U, Calais J. 2020. Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med. 61(8):1171–1177.
   PubMed Web of Science ®Google Scholar
• Mikulová MB, Mikuš P. 2021. Advances in development of radiometal labeled amino acid-based compounds for cancer imaging and diagnostics. Pharmaceuticals (Basel). 14(2):167.
   PubMedGoogle Scholar
• Mohtavinejad N, Shafiee Ardestani M, Khalaj A, Pormohammad A, Najafi R, Bitarafan-Rajabi A, Hajiramezanali M, Amanlou M. 2020. Application of radiolabeled peptides in tumor imaging and therapy. Life Sci. 258:118206.
   PubMed Web of Science ®Google Scholar
• Nock BA, Maina T, Krenning EP, de Jong M. 2014. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting. J Nucl Med. 55(1):121–127.
   PubMed Web of Science ®Google Scholar
• Oduwole OO, Poliandri A, Okolo A, Rawson P, Doroszko M, Chrusciel M, Rahman NA, Serrano de Almeida G, Bevan CL, Koechling W, et al. 2021. Follicle-stimulating hormone promotes growth of human prostate cancer cell line-derived tumor xenografts. FASEB J. 35(4):e21464.
   PubMed Web of Science ®Google Scholar
• Olejar T, Vetvicka D, Boucek J, Zabrodsky M, Benes J, Kabesova M, Pouckova P. 2020. The FSHR expression in head and neck squamous cell cancer. A pilot immunohistochemical study. Anticancer Res. 40(1):349–356.
   PubMed Web of Science ®Google Scholar
• Pan D, Liu G, Xu Y, Wang Y, Yue Y, Wang L, Yan J, Wang X, Yang R, Yang M. 2017. PET imaging of FSHR expression in tumors with 68Ga-labeled FSH1 peptide. Contrast Media Mol Imaging. 2017:2674502.
   PubMed Web of Science ®Google Scholar
• Pan D, Yan Y, Yang R, Xu YP, Chen F, Wang L, Luo S, Yang M. 2014. PET imaging of prostate tumors with 18F-Al-NOTA-MATBBN. Contrast Media Mol Imaging. 9(5):342–348.
   PubMed Web of Science ®Google Scholar
• Panza S, Giordano F, De Rose D, Panno ML, De Amicis F, Santoro M, Malivindi R, Rago V, Aquila S. 2020. FSH-R human early male genital tract, testicular tumors and sperm: its involvement in testicular disorders. Life. 10(12):336.
   Google Scholar
• Perales-Puchalt A, Wojtak K, Duperret EK, Yang X, Slager AM, Yan J, Muthumani K, Montaner LJ, Weiner DB. 2019. Engineered DNA vaccination against follicle-stimulating hormone receptor delays ovarian cancer progression in animal models. Mol Ther. 27(2):314–325.
   PubMed Web of Science ®Google Scholar
• Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, Fromont G, Hai MT, Ghinea N. 2010. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med. 363(17):1621–1630.
   PubMed Web of Science ®Google Scholar
• Siraj MA, Pichon C, Radu A, Ghinea N. 2012. Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib. J Cell Mol Med. 16(9):2010–2016.
   PubMed Web of Science ®Google Scholar
• Song K, Dai L, Long X, Wang W, Di W. 2020. Follicle-stimulating hormone promotes the proliferation of epithelial ovarian cancer cells by activating sphingosine kinase. Sci Rep. 10(1):13834.
   PubMed Web of Science ®Google Scholar
• Sun D, Bai M, Jiang Y, Hu M, Wu S, Zheng W, Zhang Z. 2020. Roles of follicle stimulating hormone and its receptor in human metabolic diseases and cancer. Am J Transl Res. 12(7):3116–3132.
   PubMed Web of Science ®Google Scholar
• Wang X-Y, Wang Y, Wu Q, Liu J-J, Liu Y, Pan D-H, Qi W, Wang L-Z, Yan J-J, Xu Y-P, et al. 2021. Feasibility study of 68Ga-labeled CAR T cells for in vivo tracking using micro-positron emission tomography imaging. Acta Pharmacol Sin. 42(5):824–831.
   PubMed Web of Science ®Google Scholar
• Xu Y, Pan D, Zhu C, Xu Q, Wang L, Chen F, Yang R, Luo S, Yang M, Yan Y. 2014. Pilot study of a novel (18)F-labeled FSHR probe for tumor imaging. Mol Imaging Biol. 16(4):578–585.
   PubMed Web of Science ®Google Scholar
• Yan J, Lu Y, Chen G, Yang M, Gu Z. 2018. Advances in liquid metals for biomedical applications. Chem Soc Rev. 47(8):2518–2533.
   PubMed Web of Science ®Google Scholar
• Zhang M, Liu Q, Zhang M, Cao C, Liu X, Zhang M, Li G, Xu C, Zhang X. 2020. Enhanced antitumor effects of follicle-stimulating hormone receptor-mediated hexokinase-2 depletion on ovarian cancer mediated by a shift in glucose metabolism. J Nanobiotechnology. 18(1):161.
   PubMed Web of Science ®Google Scholar
• Zhou N, Liu C, Guo X, Xu Y, Gong J, Qi C, Zhang X, Yang M, Zhu H, Shen L, et al. 2021. Impact of 68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring. Eur J Nucl Med Mol Imaging. 48 (1):161–175.
   PubMed Web of Science ®Google Scholar
• Zhu C, Xu Q, Pan D, Xu Y, Liu P, Yang R, Wang L, Sun X, Luo S, Yang M. 2016. Prostate cancer imaging of FSHR antagonist modified with a hydrophilic linker. Contrast Media Mol Imaging. 11(2):99–105.
   PubMed Web of Science ®Google Scholar